The correlation between Elmiron and pigmentary maculopathy was recently studied by researchers at the Emory University Medical School. The researchers observed that those treated for interstitial cystitis with Elmiron on a long-term protocol between 2015 and 2017 were at an increased risk of developing retinal maculopathy. These subjects reported significant difficulty reading and adapting in low-light situations. The researchers concluded that a connection exists between pigmentary maculopathy and chronic exposure to Elmiron that requires further research. They also urged patients who have taken Elmiron to be regularly screened by an ophthalmologist if they experience unusual vision symptoms and discontinue the drug if they are diagnosed with an eye disease.
The symptoms of pigmentary retinal maculopathy include:
- Pain in the eye;
- Vision irregularities;
- Vision changes in low light; and
- Permanent vision loss
Multiple individuals that were prescribed Elmiron have already filed product liability lawsuits seeking compensation for injuries and other losses they have suffered due to the previously undisclosed risks from this dangerous drug. If you have taken Elmiron and have experienced any of the above-listed injuries, call Suthers & Harper at 1-800-320-3284, or fill out a contact form at the firm’s website to discuss your potential Elmiron lawsuit. The firm has represented many victims injured by dangerous drugs and defective medical products. Such cases are pursued under a contingency fee basis, meaning that there are no attorney fees unless a recovery is obtained. If you or a loved one has suffered one of the serious injuries listed above, you should not delay in consulting with an attorney who is experienced in handling dangerous drug cases.